Please login to the form below

Not currently logged in
Email:
Password:

quarterly sales

This page shows the latest quarterly sales news and features for those working in and with pharma, biotech and healthcare.

AZ agrees to $320m deal for Zoladex

AZ agrees to $320m deal for Zoladex

products. The deal, which is expected to close by the end of March, will see AZ receive a $250m upfront payment for the rights, with double-digit quarterly sales-based payments ... ongoing. A further $70m is also up for grabs should Zoladex (goserelin

Latest news

  • GSK's Witty ends on a high, but warns 2017 looking 'uncertain' GSK's Witty ends on a high, but warns 2017 looking 'uncertain'

    Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline. ... Other generics from Mylan and Hikma are under regulatory review, however, which could be directly substitutable and accelerate the decline in the brand's

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    The last AZ drug to fall over the 'patent cliff' - cholesterol-lowerer Crestor (rosuvastatin) - saw sales cut in half in the fourth quarter after the loss of US patent protection, with ... The decline was, however, offset by good growth for non-small

  • Tecentriq growth offsets Avastin's US decline at Roche Tecentriq growth offsets Avastin's US decline at Roche

    Roche is hoping that while Avastin is likely to see some cannibalisation of sales from Tecentriq, combination use could support its older drug. ... Overall, Roche reported a 3% increase in pharma sales to CHF 39bn, and the company is expecting low- to mid

  • AbbVie weak on new drug sales, but Humira stays strong AbbVie weak on new drug sales, but Humira stays strong

    AbbVie weak on new drug sales, but Humira stays strong. World’ s biggest-selling drug has record quarter while Imbruvica and Venclexta fall short. ... Imbruvica - which is also sold by Johnson &Johnson - should hit $2.4bn in sales this year, of which

  • J&J pondering future of diabetes device assets J&J pondering future of diabetes device assets

    J&J pondering future of diabetes device assets. Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales. ... The diabetes care announcement came as J&J's fourth quarter sales fell below analyst estimates, with top-selling drug

More from news
Approximately 9 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics